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Abstract
Background A clinical–genetic function (Cardio in-
Code) was generated using genetic variants associated
with coronary heart disease (CHD), but not with classical
CHD risk factors, to achieve a more precise estimation of
the CHD risk of individuals by incorporating genetics into
risk equations [Framingham and REGICOR (Registre
Gironı´ del Cor)].
Objective The objective of this study was to conduct an
economic analysis of the CHD risk assessment with Cardio
inCode, which incorporates the patient’s genetic risk into
the functions of REGICOR and Framingham, compared
with the standard method (using only the functions).
Methods A Markov model was developed with seven
states of health (low CHD risk, moderate CHD risk, high
CHD risk, CHD event, recurrent CHD, chronic CHD, and
death). The reclassification of CHD risk derived from
genetic information and transition probabilities between
states was obtained from a validation study conducted in
cohorts of REGICOR (Spain) and Framingham (USA). It
was assumed that patients classified as at moderate risk by
the standard method were the best candidates to test the
risk reclassification with Cardio inCode. The utilities and
costs (€; year 2011 values) of Markov states were obtained
from the literature and Spanish sources. The analysis was
performed from the perspective of the Spanish National
Health System, for a life expectancy of 82 years in Spain.
An annual discount rate of 3.5 % for costs and benefits was
applied.
Results For a Cardio inCode price of €400, the cost
per QALY gained compared with the standard method
[incremental cost-effectiveness ratio (ICER)] would be
€12,969 and €21,385 in REGICOR and Framingham
cohorts, respectively. The threshold price of Cardio in-
Code to reach the ICER threshold generally accepted
in Spain (€30,000/QALY) would range between €668
and €836. The greatest benefit occurred in the subgroup
of patients with moderate–high risk, with a high-risk
reclassification of 22.8 % and 12 % of patients and an
ICER of €1,652/QALY and €5,884/QALY in the
REGICOR and Framingham cohorts, respectively. Sen-
sitivity analyses confirmed the stability of the study
results.
Conclusions Cardio inCode is a cost-effective risk score
option in CHD risk assessment compared with the standard
method.
A. Ramı´rez de Arellano  A. Gracia  A. Boldeanu
Departamento Cientı´fico, FERRER INCODE, Barcelona, Spain
A. Coca
Hospital Clı´nic de Barcelona, Barcelona, Spain
M. de la Figuera
EAP Sardenya, Unidad Docente ACEBA, Barcelona, Spain
C. Rubio-Terre´s  D. Rubio-Rodrı´guez (&)
HEALTH VALUE, Virgen de Ara´nzazu, 21-5B,
28034 Madrid, Spain
e-mail: drubiorodriguez@healthvalue.org
J. Puig-Gilberte  E. Salas
GENDIAG, Barcelona, Spain
Appl Health Econ Health Policy (2013) 11:531–542
DOI 10.1007/s40258-013-0053-x
Key Points for Decision Makers
• Cardio inCode is a clinical–genetic function for
coronary heart disease (CHD) risk assessment.
• For a Cardio inCode price of €400 in Spain, the cost
per QALY compared with the standard method would
be €12,969 and €21,385 in REGICOR (Registre Gir-
onı´ del Cor) and Framingham cohorts, respectively.
• The greatest benefit in Spain occurred in the subgroup
of patients with moderate–high CHD risk, with a cost
per QALY of €1,652 (REGICOR) and €5,884 (Fra-
mingham).
1 Introduction
Cardiovascular disease is the most common cause of death
in Europe. Despite acquired knowledge, the demonstrated
efficacy of preventive and therapeutic measures, as well as
the availability of regional, national, and European guide-
lines and plans for the prevention of cardiovascular disease,
the mortality due to cardiovascular disease continues to be
high in Europe [1–4]. Cardiovascular disease is responsible
for 31 % of all deaths in Spain, making it the main cause of
death, with coronary heart disease (CHD) being the most
frequent [5, 6].
Since the publication of the first European Guidelines on
Prevention of CHD in 1994 [7] the assessment of CHD risk
has been recommended as an essential screening tool in the
management of patients in all guideline updates. The car-
diovascular prevention approach of calculating the CHD
risk has become an important criterion to establishing the
intensity of preventive efforts [8]. Global CHD risk better
describes the overall risk profile and is preferred to the
assessment of risk factors separately. In Spain, the
assessment of CHD risk is mainly performed using the
original Framingham Risk Score [9], risk equations based
on the Framingham Risk Score such as the REGICOR
(Registre Gironı´ del Cor) Risk Score [10, 11], or the
SCORE (Systematic COronary Risk Evaluation) function
re-calibrated for Spain [12]. Although very useful for
screening, the current equations have a modest sensitivity
and specificity [13]. From a clinical perspective, the low
precision of risk function prediction is illustrated by the
fact that 53.6 % of cardiovascular events in a population
aged 35–74 years occur in individuals classified as mod-
erate CHD risk [14–16].
CHD is a disease of complex etiology involving genetic
and environmental factors, as well as the interaction
between them [13]. It is estimated that genetic factors
explain between 40 and 55 % of the variability in the
population for the onset of CHD [13, 14]. Several genome-
wide association studies have been conducted over the past
few years that have consistently identified genetic variants
associated with CHD [17–23]. Some of these genetic
variants are in turn associated with some classic CHD risk
factors, although others are independent of the classical
factors. The discovery of these genetic variants indepen-
dently associated with CHD may enable the identification
of new etiopathogenic mechanisms of the disease, as well
as new therapeutic targets. Furthermore, these variants
could be used as new biomarkers to improve the CHD risk
prediction ability, or the reclassification of individuals at
moderate risk, by providing additional information to that
already included in the classic risk functions [24]. As a
result, a more correct estimation of the risk, particularly in
individuals with moderate risk, could have a significant
impact on the total CHD risk, and on the effectiveness of
population preventive strategies [15].
A clinical–genetic function (Cardio inCode) was
generated using genetic variants associated with CHD but
not with classical CHD risk factors, to achieve a more
precise estimation of the CHD risk of individuals by
incorporating genetics into risk equations (Framingham
and REGICOR). Cardio inCode has been validated in
studies that have used Framingham and REGICOR
cohorts, following the recommendations of the American
Heart Association [25]. These two cohorts have been used
in order to validate Cardio inCode in two populations
with a different prevalence of CHD (Framingham, with an
elevated prevalence, and REGICOR, with a low preva-
lence of CHD) [15]. The quantitative results of the vali-
dation study of Cardio inCode are described in ‘‘Cardio
inCode Effectiveness’’.
The present study aims to perform a cost-effectiveness
analysis of the evaluation of the risk of suffering a CHD
event in Spain using Cardio inCode compared with the
standard method (applying the Framingham or REGICOR
functions alone).
2 Methods
Cost-effectiveness analysis is a tool of special importance
for making decisions in a National Health System (NHS).
This type of analysis was performed in order to assess the
efficiency of evaluating the risk of suffering a CHD event
in Spain using Cardio inCode and comparing it with the
standard method (applying the Framingham or REGICOR
functions alone).
2.1 Model
A Markov model [26] was prepared with the structure
presented in Fig. 1, with a time horizon (duration of the
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simulation, for a joint life expectancy in men and women
of 82 years) [27] of 28 years for the REGICOR cohort
(start of the simulation at 54 years of age), and 26 years for
the Framingham cohort (start of the simulation at 56 years
of age), according to the validation study of the predictive
ability of CHD risk estimation by Cardio inCode in both
patient cohorts [15]. Table 1 summarizes the seven health
states used in the model, as well as their definitions. The
primary variables used in the study were the costs, the
utilities (patient perceived quality of life, expressed as
QALYs) of the health states, the transition probabilities
between them, and the survival expressed as life-years
(LYs).
2.2 Cardio inCode Effectiveness
For the purpose of the model, it was assumed that the
patients classified as moderate risk using the standard
method could be subjected to an evaluation of CHD risk
with Cardio inCode, being able to reclassify them cor-
rectly (in part) to a higher or lower risk, due to its higher
sensitivity and specificity. For example, in the case of the
REGICOR cohort, 23.14 % of patients with moderate cor-
onary risk using the standard method are correctly reclas-
sified [15]. In the model, only the patients reclassified to a
higher risk (6.3 % of patients with moderate coronary risk
using the standard method) are considered as that reclassi-
fication will have an economic impact since more
demanding preventive and/or therapeutic objectives would
be established for them. The reclassification values of the
CHD risk (Table 2) were obtained from the validation study
of Cardio inCode, which found it to be linearly associated
with CHD in the two population-based cohorts: the REGI-
COR Study (n = 2,351) and the Framingham Heart Study
(n = 3,537) [meta-analyzed hazard ratio (95 % CI) *1.13
(1.01–1.27), per unit]. Inclusion of the multilocus genetic
risk score (Cardio inCode) in the Framingham risk func-
tion improved its discriminative capacity in the Framing-
ham sample (c-statistic 72.81 vs. 72.37, p = 0.042) but not
in the REGICOR sample. According to both the net
reclassification improvement (NRI) index and the inte-
grated discrimination index (IDI), the genetic risk score
improved re-classification among individuals with
Fig. 1 Markov economic model for the evaluation of Cardio
inCode, a clinical–genetic function for estimating the coronary
heart disease risk by including the genetic risk, represented schemat-
ically as an influence diagram. Reclassification of the coronary heart
disease risk in patients from the cohorts of REGICOR (Registre
Gironı´ del Cor) and Framingham, all initially classified as moderate
risk with the standard method [the usual method for estimating
coronary heart disease risk, without a genetic risk score (Framingham
or REGICOR functions)] [15]. Low risk: \5 and \10 %; moderate–
low risk: 5–9.9 and 10–14.9 %; moderate–high risk: 10–14.9 and
15–19.9 %; high risk: C15 and C20 % in REGICOR and Framing-
ham functions, respectively. CHD coronary heart disease
Table 1 Definitions of the
Markov states
CHD coronary heart disease,
REGICOR Registre Gironı´ del
Cor
Markov states Definition References
Low CHD risk CHD risk with a score of 0–4.9 % on the REGICOR
scale or 5–9.9 % on the Framingham scale
[10, 11, 15]
Moderate–low CHD risk CHD risk with a score of 5–9.9 % on the REGICOR
scale or 10–14.9 % on the Framingham scale
[10, 11, 15]
Moderate–high CHD risk CHD risk with a score of 10–14.9 % on the REGICOR
scale or 15–19.9 % on the Framingham scale
[10, 11, 15]
High CHD risk CHD with a score of C15 % on the REGICOR scale or
C20 % on the Framingham scale
[10, 11, 15]
CHD acute event (year 1) CHD, including acute myocardial infarction, with or





Patient who survived a CHD event –
Recurrent CHD events
(following years)
Repetitive CHD events, which may occur in the same
year or in the years following the occurrence of the
first event
–
Death Due to CHD or by other causes –
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moderate CHD risk [meta-analysis NRI (95 % CI) 17.44
(8.04; 26.83)], but not overall [15]. The main characteristics
of the patients included, corresponding to the REGICOR
and Framingham populations, respectively, were as fol-
lows: (1) age 53.9 [standard deviation (SD) 11.2] and 56.0
(SD 9.3) years; (2) percentage males 47.8 and 43.5 %; (3)
systolic blood pressure 132 (SD 20.8) and 127 (SD 18.3)
mmHg; (4) diastolic blood pressure 79.5 (SD 10.4) and 75.0
(SD 9.8) mmHg; (5) percentage smokers 22 and 20.2 %; (6)
total cholesterol 225 (SD 42.4) and 210 (SD 38.6) mg/dL;
(7) high-density lipoprotein (HDL) cholesterol 51.7 (SD
13.3) and 51 (SD 15.2) mg/dL; and (8) percentage with
diabetes mellitus 13.8 and 6.4 % [15].
2.3 Transition Probabilities
The transition probabilities between the health states for
the REGICOR and Framingham cohorts were obtained
from the results of the validation study [15] and other
sources [2–4, 28–33] and are summarized in Table 3. The
transition probabilities for Cardio inCode effectiveness
(defined as the correct reclassification to a higher risk)
adopted in the model were calculated from patients
reclassified to higher risk and who had coronary events.
The transition probabilities between the health states were
calculated using the following formula [34]:
p ¼ 1  ert
where p is the transition probability from one determined
state to another, and r is the percentage of patients who transit
in the time t (annually in this model) between those states.
The annual probability of suffering a CHD event from
each risk level was also obtained from the Cardio inCode
validation study [15]. According to the economic analysis
by Wald et al. [2] and the two clinical trial meta-analyses
by Law et al. [3, 4], the reduction of the risk of suffering
from a coronary disease in patients with a plausible pre-
vention strategy [standard treatment with statins (HMG-
CoA reductase inhibitors) and antihypertensive drugs] was
estimated to be 24.4 % in the first year of treatment,
53.3 % in the second year, 73.3 % in the third year, and
80 % annually in the following years. These risk reduction
rates were applied to the patients reclassified to high CHD
risk (Table 3).
The base-case analysis already includes adherence to
drug treatment in the calculations, because (according to
the meta-analysis by Law et al. [4]) over all of the trials,
25 % of participants stopped taking their allocated drugs.
The probability of death unrelated to CHD from 56 years
(mean age of Framingham cohort) or 54 years (mean age
of REGICOR cohort) was estimated until 82 years (life
expectancy in Spain) from data from the Spanish National
Statistics Institute [28].
The mortality in the acute phase of a CHD event
(throughout the 12 months following its occurrence) was
obtained from two Spanish studies [29, 30]. The proba-
bility of a recurrent CHD was calculated from the studies
by Ara et al. [31, 33] and according to available Spanish
data [29, 32]. Finally, the probability of death by recurrent
CHD was calculated from the study by Ahumada et al.
[32] (Table 3).
Table 2 Reclassification of coronary heart disease risk (%) as a
result of its evaluation with Cardio inCode instead of the standard
method [15]




Continue in moderate CHD risk 77.4
Are reclassified to a high CHD risk 6.3
Are reclassified to a low CHD risk 16.3
Framingham cohort
Continue in moderate CHD risk 88.8
Are reclassified to a high CHD risk 4.3
Are reclassified to a low CHD risk 6.9
Moderate–low
REGICOR cohort
Continue in moderate–low CHD risk 64.5
Are reclassified to a high or moderate–high
CHD risk
14.7
Are reclassified to a low CHD risk 20.8
Framingham cohort
Continue in moderate–low CHD risk 80.1
Are reclassified to a high or moderate–high
CHD risk
9.2
Are reclassified to a low CHD risk 10.7
Moderate–high
REGICOR cohort
Continue in moderate–high CHD risk 51.4
Are reclassified to a high CHD risk 22.8




Continue in moderate–high CHD risk 72.4
Are reclassified to a high CHD risk 12.0
Are reclassified to a low or moderate–low CHD
risk
15.6
CHD coronary heart disease, REGICOR Registre Gironı´ del Cor
a It is assumed (for purposes of the model) that some of the patients
classified as moderate CHD risk using the standard method would be
reclassified to a higher or lower CHD risk, if they were subjected to a
new CHD risk evaluation with Cardio inCode, in accordance with its
validation study
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Table 3 Annual probabilities of transition between Markov states
From state… To state… Correct identification
of risk/age
Mean Pt Maximum–minimum Pt References
REGICOR cohort
Moderate CHD risk CHD event No 0.00737 0.00664–0.00811 [15]
CHD event (year 1) Yes 0.00558 0.00502–0.00613 [2–4, 15]
CHD event (year 2) Yes 0.00261 0.00235–0.00287 [2–4, 15]
CHD event (year 3) Yes 0.00070 0.00063–0.00077 [2–4, 15]
CHD event (following years) Yes 0.00014 0.00013–0.00015 [2–4, 15]
High CHD risk CHD event No 0.02518 0.02266–0.02770 [15]
CHD event (year 1) Yes 0.01908 0.01717–0.02099 [2–4, 15]
CHD event (year2) Yes 0.00895 0.00806–0.00985 [2–4, 15]
CHD event (year 3) Yes 0.00239 0.00216–0.00263 [2–4, 15]
CHD event (following years) Yes 0.00048 0.00043–0.00053 [2–4, 15]
Low CHD risk CHD event No 0.00160 0.00144–0.00176 [15]
CHD event (year 1) Yes 0.00121 0.00109–0.00133 [2–4, 15]
CHD event (year 2) Yes 0.00056 0.00051–0.00062 [2–4, 15]
CHD event (year 3) Yes 0.00015 0.00014–0.00017 [2–4, 15]
CHD event (following years) Yes 0.00003 0.00003–0.00003 [2–4, 15]
Any CHD risk Death due to other causes 50–54 years 0.00068 0.00061–0.00075 [28]
55–59 years 0.00100 0.00090–0.00110 [28]
60–64 years 0.00148 0.00133–0.00163 [28]
65–69 years 0.00225 0.00202–0.00247 [28]
70–74 years 0.00362 0.00326–0.00399 [28]
75–79 years 0.00642 0.00578–0.00706 [28]
80–84 years 0.01177 0.01059–0.01295 [28]
CHD event Death due to CHD – 0.11156 0.10041–0.12272 [29, 30]
Chronic CHD Recurrent CHD – 0.02883 0.02594–0.03171 [29, 31–33]
Recurrent CHD Death due to recurrent CHD – 0.29874 0.26886–0.32861 [32]
Framingham cohort
Moderate CHD risk CHD event No 0.01015 0.00913–0.01116 [15]
CHD event (year 1) Yes 0.00768 0.00691–0.00844 [2–4, 15]
CHD event (year 2) Yes 0.00359 0.00323–0.00395 [2–4, 15]
CHD event (year 3) Yes 0.00096 0.00086–0.00105 [2–4, 15]
CHD event (following years) Yes 0.00019 0.00017–0.00021 [2–4, 15]
High CHD risk CHD event No 0.01941 0.01747–0.02135 [15]
CHD event (year 1) Yes 0.01470 0.01323–0.01617 [2–4, 15]
CHD event (year 2) Yes 0.00689 0.00620–0.00758 [2–4, 15]
CHD event (year 3) Yes 0.00184 0.00166–0.00203 [2–4, 15]
CHD event (following years) Yes 0.00037 0.00033–0.00041 [2–4, 15]
Low CHD risk CHD event No 0.00310 0.00279–0.00340 [15]
CHD event (year 1) Yes 0.00234 0.00211–0.00257 [2–4, 15]
CHD event (year 2) Yes 0.00109 0.00098–0.00120 [2–4, 15]
CHD event (year 3) Yes 0.00029 0.00026–0.00032 [2–4, 15]
CHD event (following years) Yes 0.00006 0.00005–0.00006 [2–4, 15]
Any CHD risk Death due to other causes 55–59 years 0.00099 0.00089–0.00109 [28]
60–64 years 0.00148 0.00133–0.00163 [28]
65–69 years 0.00225 0.00202–0.00247 [28]
70–74 years 0.00362 0.00326–0.00399 [28]
75–79 years 0.00642 0.00578–0.00706 [28]
80–84 years 0.01177 0.01059–0.01295 [28]
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2.4 Utilities
The QALYs were estimated from the utilities (measure-
ment of the perceived quality of life by the patient), which
were obtained by using the EQ-5D instrument in two
previously published British studies [31, 35] (Table 4).
Utilities obtained from Spanish patients were not used
because they are not available.
2.5 Perspective and Costs
The analysis was made from the NHS perspective, and thus
only direct health costs were included. The unit costs of the
health states are from Spanish sources [36, 37] and are
shown in Table 4.
The cost per determination of CHD risk with Cardio
inCode (€400) was provided by Ferrer inCode. To cal-
culate the cost of one determination with the standard
method, the following use of resources was assumed [37,
38]: (1) two consultations with a primary care physician
(one to request the laboratory tests and another to inform
the patient of the test results) [€34.24 each consultation];
(2) one determination in blood of total cholesterol (€11.23),
HDL cholesterol (€14.88) and glucose (€10.02); and (3)
one visit to the health center nurse to take blood pressure
(€19.73). In the case of patients evaluated with Cardio
inCode, the costs also incurred as a result of the deter-
mination with the standard method were considered. The
costs are expressed in euros (€) in year 2011 values. The
actualization of the costs was made using the inflation rates
in Spain.
2.6 Discount
In the long-term simulation performed in the model, an
annual discount of 3.5 % was made in the costs as well as
in the benefits (QALYs and LYs).
2.7 Cost-Effectiveness Analysis
Two types of analyses were performed: one deterministic,
using the mean values of all the variables (base case), and a
probabilistic analysis, by means of a Monte-Carlo simu-
lation using the extreme values of all the variables at
random [39, 40]. The following distributions were applied
to the variables: (1) Log-normal to the costs; (2) Gamma to
the utilities; and (3) Beta to the transition probabilities [30].
A hypothetical cohort of 10,000 patients was used in the
Monte-Carlo simulation and 1,000 analyses were
performed.
It was considered that Cardio inCode would be cost
effective compared with the standard method for an
incremental cost-effectiveness ratio (ICER) (willingness of
the NHS to pay) less than €30,000 (or €36,000 updating the
2002 value to the year 2011) per QALY gained or per LY
gained without adjusting for its quality [41].
2.8 Sensitivity Analysis
Finally, deterministic sensitivity analyses were performed
with extreme values of the following variables: (1) starting
with patients with a moderate–low CHD risk (5–9.9 % in
REGICOR; 10–15 % in Framingham) with a reclassifica-
tion rate to a higher risk (moderate–high and high risk) and
to a lower risk of 14.7 and 20.8 % for REGICOR and 9.2
and 10.7 % for Framingham [15], considering that the
intensive prevention approach would be carried out not
only on patients with a high CHD risk, but also in those
classified as moderate–high risk; (2) starting with patients
with a moderate–high CHD risk (10–14.9 % in REGICOR;
15–20 % in Framingham) with a reclassification rate to a
higher risk and a lower risk (high and moderate–low) of
22.8 and 25.8 % for REGICOR and 12.0 and 15.6 % for
Framingham [15]; (3) tornado analyses were performed,
modifying separately the variables of each category (costs,
utilities, and probabilities); and, finally (4) although the
base-case analysis already includes adherence [42] to drug
treatments in the calculations [3, 4], as in the study of
Greving et al. [43], we assumed additional adherence rates
of CHD prevention treatment derived from the literature
(60 % adherence after year 1, 45 % after year 2, 40 % after
year 3, and thereafter remaining stable) [44–46]. These
rates were incorporated into the model by adjusting the
reduction of the risk of suffering a CHD event in patients
with a drug prevention strategy obtained in the meta-
analyses of Law et al. [3, 4].
The Markov model was prepared using the program
TreeAge Pro Healthcare Module 2009 [47].
Table 3 continued
From state… To state… Correct identification
of risk/age
Mean Pt Maximum–minimum Pt References
CHD event Death due to CHD – 0.11156 0.10041–0.12272 [29, 30]
Chronic CHD Recurrent CHD – 0.02883 0.02594–0.03171 [29, 31–33]
Recurrent CHD Death due to recurrent CHD – 0.29874 0.26886–0.32861 [32]
CHD coronary heart disease, Pt transition probabilities between health states, REGICOR Registre Gironı´ del Cor
536 A. Ramı´rez de Arellano et al.
3 Results
3.1 Deterministic Analysis
For each patient evaluated with Cardio inCode instead of
the standard method, 0.0256 and 0.0166 QALYs, or 0.0247
and 0.0160 LYs would be gained in the REGICOR and
Framingham cohorts, respectively. For a Cardio inCode
price of €400, the additional cost per patient evaluated by
this method would be €332 and €355, respectively. Thus,
the cost of gaining a QALY compared with the standard
method (ICER) would be €12,969 and €21,385 in the
REGICOR and Framingham cohorts, respectively, and the
cost of gaining a LY would be €13,441 and €22,187,
respectively (Table 5). The threshold price of Cardio in-
Code to achieve the generally accepted maximum ICER
in Spain (€30,000/QALY) [41] would vary between €668
and €836. A large benefit would be achieved in the patient
subgroup with a moderate–high risk, with a reclassification
to high risk of 22.8 % of the patients, and an ICER of
€1,652/QALY and €5,884/QALY (REGICOR and Fra-
mingham cohorts). The deterministic sensitivity analyses
confirmed the stability of the study, obtaining ICER values
in all cases lower than the acceptability threshold. The
variables that most determined the result were the costs and
utilities of an incident and a recurrent CHD event, the
utility of the moderate CHD risk, and the probability of
recurrent CHD, as well as the CHD preventive treatment
adherence variable. When adherence rates of CHD pre-
vention treatment derived from the literature were
assumed, the cost per QALY gained compared with the
standard method (ICER) would be €20,350 and €29,396 in
the REGICOR and Framingham cohorts, respectively.
According to the tornado diagram (Fig. 2), the variables
that most determine the outcome are the utilities of mod-
erate, low, and high CHD risk health states (for REGICOR
cohort) and the CHD event probability (moderate risk),
CHD event cost, and CHD death probability (for Fra-
mingham cohort). However, the value of ‘net monetary
benefit’ indicates that (for a willingness to pay €30,000)
Cardio inCode was a cost-effective option for all modified
variables.
3.2 Probabilistic Analysis (Monte-Carlo Simulation)
Taking the QALY as the effectiveness variable, Cardio
inCode was the most cost-effective option compared
with the standard method (for a willingness to pay less
than €30,000 or €36,000 per QALY gained) in 82.0 and
89.5 %, respectively, of the simulations performed on the
REGICOR cohort, and 65.7 and 73.7 %, respectively, of
the simulations performed on the Framingham cohort
(Fig. 3).
4 Discussion
In accordance with the method used in this study, the
Cardio inCode clinical–genetic test is a cost-effective
option in the evaluation of CHD risk, compared with the
standard method, in patients with moderate CHD risk, with
a higher benefit particularly in the moderate- to high-risk
patients subgroup.
In assessing the results of the study we must take into
account study limitations as well as strengths. The main
limitation is that we have used a theoretical model, which
is by definition a simplified simulation of reality. However,
the cost-effectiveness analysis was made using a Markov
model [26] with Monte-Carlo probabilistic analyses [40],
Table 4 Utilities and unit costs of the health states [data given as
mean value (minimum–maximum)]
Health state Utility References
Utilities
Low CHD risk 0.872 (0.849–0.894)a [35]
Moderate CHD risk 0.849 (0.827–0.871)b [31, 35]
High CHD risk 0.826 (0.805–0.848)c [31]
CHD event 0.746 (0.727–0.766)d [31]
Recurrent CHD 0.671 (0.654–0.689)e [31]
Chronic CHD (following years) 0.800 (0.779–0.821)f [35]
Health state Cost (€; 2011 values) References
Unit costs
Low CHD risk (annual) 1,109 (1,067–1,151)g [36]
Moderate CHD risk (annual) 1,148 (1,122–1,175)g [36]
High CHD risk (annual) 1,327 (1,277–1,378)g [36]
CHD (year 1) and recurrent
CHD (following years)
6,121 (2,801–9,102)h [37]
Chronic CHD (following years) 1,411 (1,348–1,475)i [36]
CHD coronary heart disease, DRG Diagnosis Related Group, REGICOR
Registre Gironı´ del Cor
a Interval: ±2.6 % (variation of the estimated value for high CHD risk)
b Average of the utilities of the low and high CHD risks
c Patients 55 years of age (average age of the REGICOR and Framingham
studies). The interval should correspond to the utilities for 50 and 60 years
of age
d Average of the utilities of the following CHD: stable angina (0.808),
unstable angina (0.731), and myocardial infarction (0.700). Interval:
±2.6 %
e Utility 10 % less than that of the CHD, in accordance with Ara et al.
[31]
f Utility in the years following CHD (unstable angina and myocardial
infarction). Interval: ±2.6 %
g Total cost of a patient in primary care, according to CHD risk [36]
h Average cost of the following DRGs: 121, 122, 123, and 140. Interval:
cost of DRG 140 (minimum) and 123 (maximum)
i It is assumed that the cost of the state of chronic CHD corresponds to a
very high CHD risk (C30 % on the Framingham scale) [36]
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thus providing a more realistic simulation of the long-term
progression of the disease than deterministic models.
The utilities were obtained from two British studies
using the EQ-5D instrument [31, 35] and these utilities may
not be applicable to the Spanish population, which is
another possible limitation. However, in a study based on
83,000 evaluations of 44 states of health with EQ-5D
carried out in six European countries, including Spain,
there was a higher variability between individuals than
between countries [48].
Another possible limitation is that the minimum clini-
cally significant difference in the utility of two health
interventions is generally situated around 0.030 QALYs
[49, 50] and the gains in QALYs observed in each patient
evaluated with Cardio inCode, in comparison with the
standard method, were 0.0256 QALYs for REGICOR and
0.0166 QALYs for Framingham. Thus, it could be con-
sidered that the differences observed in utilities are very
close to clinical significance in the Spanish cohort of the
REGICOR study, although not in the Framingham cohort.
However, these individual results, transferred to a
hypothetical cohort of 1,000 patients initially classified as
moderate CHD risk with the standard method would lead to
a relevant gain of 25.6 and 16.6 QALYs in REGICOR and
Framingham patients, respectively.
The last possible limitation is that the efficiency of
treating all patients with moderate CHD risk has not been
compared with the option of treating only those patients
who were reclassified to high CHD risk after applying
Cardio inCode in this model. This would be an interesting
future analysis.
One of the strengths of this study is that the reclassi-
fication rates with Cardio inCode were obtained in a
validation study [15] that included 2,351 Spanish patients
from the cohort of the REGICOR study and 3,537 US
patients from the cohort of the Framingham study.
Another strength is that the transition probabilities
between different health states were calculated from that
validation study, clinical trials meta-analyses [3, 4], and
Spanish studies [29, 30, 32].
Another strength is that all of the costs used in the study
were taken from Spanish sources [36–38]. In particular, the
Table 5 Results of the
deterministic cost-effective
analysis. Base case (from
moderate coronary heart disease
risk) and sensitivity analysis
(from moderate–low and
moderate–high coronary heart
disease risk) in the REGICOR
and Framingham cohorts




difference), LY life-years, LYG
life-years gained, REGICOR
Registre Gironı´ del Cor




From moderate CHD risk
REGICOR cohort
Cardio inCode 20,016 13.7015 16.1622 12,969 13,441
Standard 19,684 13.6759 16.1375
Differences 332 0.0256 0.0247
Framingham cohort
Cardio inCode 20,195 13.6216 16.1182 21,385 22,187
Standard 19,840 13.6050 16.1022
Differences 355 0.0166 0.0160
From moderate–low CHD risk
REGICOR cohort
Cardio inCode 20,143 13.7126 16.1839 4,037 4,184
Standard 19,902 13.6529 16.1263
Differences 241 0.0597 0.0576
Framingham cohort
Cardio inCode 20,249 13.6356 16.1334 8,511 8,834
Standard 19,946 13.6000 16.0991
Differences 303 0.0356 0.0343
From moderate–high CHD risk
REGICOR cohort
Cardio inCode 20,257 13.7269 16.2057 1,652 1,711
Standard 20,104 13.6343 16.1163
Differences 153 0.0926 0.0894
Framingham cohort
Cardio inCode 20,245 13.6584 16.1462 5,884 6,107
Standard 19,972 13.6120 16.1015
Differences 273 0.0464 0.0447
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costs associated with the CHD risk states were obtained
from a Spanish cross-sectional study using a retrospective
review of the medical records of 12,828 patients followed
up as outpatients in seven primary care centers [36].
A final strength is that the results of the model were very
stable, with probabilities of obtaining ICERs lower than
€30,000 or €36,000 per QALY gained of 82.0 and 89.5 %,
respectively, in the REGICOR cohort and 65.7 and 73.7 %,
respectively, in the Framingham cohort. The ICERs were
even lower in the scenario of adherence rates of CHD
prevention treatment derived from the literature without
considering the expected positive effect of genetic infor-
mation on the motivation to adhere to risk-reducing
behaviors and treatment based on published results for
other conditions [51, 52].
To our knowledge, this is the first economic analysis on
the efficiency of a genetic-based CHD risk score. This study
indicates that the clinical–genetic evaluation of CHD risk
with Cardio inCode is cost effective compared with the
standard evaluation method in patients with moderate risk.
According to the European Guidelines on Cardiovas-
cular Prevention and its Spanish adaptation by the Spanish
Interdisciplinary Committee for Cardiovascular Prevention
(CEIPC) of 2008 (http://www.CEIPC.org), pharmacologi-
cal treatment for the prevention of CHD and therapeutic
objectives in relation to the CHD risk in high-risk patients
are one of the priorities in cardiovascular prevention. For
this reason, the patients who would most benefit from
Cardio inCode would be those with a moderate–high




Net Monetary Benefit (wtp=30000)
383000 385000 387000 389000 391000 393000 395000 397000 399000
Moderate CHD risk utility: 0.827 to 0.871
Low CHD risk utility: 0.849 to 0.894
High CHD risk utility: 0.805 to 0.848
CHD event probability (moderate CHD risk unidentify; REGICOR): 0.00789 to 0.00964
Chronic CHD utility: 0.779 to 0.821
CHD/recurrent event cost: 2801.91 to 9102.26 Euros
Moderate CHD risk annual cost: 1122.03 to 1175.43 Euros
Death due to CHD probability (REGICOR): 0.10041 to 0.12272
Recurrent CHD event probability (RECICOR): 0.02594 to 0.03171
Low CHD risk annual cost: 1067.29 to 1151.53 Euros
Death due to recurrent CHD probability: 0.26886 to 0.32861
Cardio inCode® test cost: 400 to 590 Eur
CHD event utility: 0.727 to 0.766
Chronic CHD cost (following years): 1348.47 to 1475.05 Euros
High CHD risk annual cost: 1277.69 to 1378.13
CHD event probability (low CHD risk unidentify; REGICOR): 0.00216 to 0.00264
CHD recurrent event utility: 0.654 to 0.689
Death due to other causes probability: 0.00089 to 0.00109
Standard method cost: 99.47 to 149.21 Euros
CHD event probability (low CHD risk; with Cardio inCode®): 0.00279 to 0.00340
CHD event probability (high CHD risk unidentify; REGICOR): 0.01694 to 0.02070




Net Monetary Benefit (wtp=30000 Euros)
462700 462900 463100 463300 463500 463700 463900 464100
CHD event probability (moderate risk, FRAMINGHAM): 0,00913 to 0,01116
CHD event cost: 2801,91 to 9102,26 Euros
Death due to CHD probability: 0,10041 to 0,12272
CHD moderate risk cost: 1122,03 to 1175,43 Euros
Second CHD probability: 0,02594 to 0,03171
Death due to second CHD probability: 0,26886 to 0,32861
Cardio inCode® test cost: 499,47 to 739,21 Euros
Chronic CHD (following years) cost: 1348,47 to 1475,05 Euros
Low CHD risk (annual) cost: 1067,29 to 1151,53 Euros
High CHD risk (annual) cost: 1277,69 to 1378,13 Euros
CHD event probability (low CHD risk unidentify; FRAMINGHAM): 0,00279 to 0,00340
Moderate CHD risk utility: 0,827 to 0,871
Low CHD risk utility: 0,849 to 0,894
Chronic CHD utility: 0,779 to 0,821
CHD event recurrent utility: 0,654 to 0,689
CHD event utility: 0,727 to 0,766
Death due to other causes probability: 0,00089 to 0,00109
Standard method cost: 99,47 to 149,21 Euros
CHD event probability (high CHD risk unidentify; FRAMINGHAM): 0,01747 to 0,02135
Fig. 2 Deterministic sensitivity analysis results: a cohort of REGICOR (Registre Gironı´ del Cor); b cohort of Framingham. CHD coronary heart
disease, wtp willingness to pay (€) per QALY gained
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who have, in reality, a higher risk and, therefore, the most
adequate preventive strategies and therapeutic objectives
will be established for the most effective prevention of
CHD.
5 Conclusion
Cardio inCode improves risk reclassification for moderate
CHD risk and particularly in the population at moderate–
high CHD risk. This potential value, if confirmed in clin-
ical practice [53], would be cost effective.
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